NeuroScientific
BIOPHARMACEUTICALS
ASX:NSB

ASX ANNOUNCEMENT
1 AUGUST 2023

ISSUANCE OF ORDINARY SHARES

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (**"NeuroScientific"** or **"the company"**) provides this notice the Company has issued 1,133,227 fully paid ordinary shares under 12-month voluntary escrow.

The shares have been issued in line with the Company Prospectus in relation to the Licence Agreement with the University of Tasmania for Consideration Milestone 2, upon completion of the additional animal efficacy study, issue of ordinary shares to the value of $200,000 at the same price per share as the Company's most recent capital raise.

The issue also relates to the payment of approximately $42k for additional Licence agreement costs incurred by the University of Tasmania on the Company's behalf.

All shares were issued under the Company's Listing Rule 7.1 placement capacity.

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Paul Rennie
Chairman and Interim CEO
ir@neuroscientific.com
+ 61 8 6382 1805

Abby Macnish-Niven
CFO and Company Secretary
ir@neuroscientific.com
+ 61 8 6382 1805

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.